DS-8201a
D967MC00001
Phase 2 small_molecule active
Quick answer
DS-8201a for Treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless of tumor histology is a Phase 2 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless of tumor histology
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active